Ads
related to: alternative for famotidine
Search results
Results from the WOW.Com Content Network
The H 2 receptor antagonists are a class of drugs used to block the action of histamine on parietal cells in the stomach, decreasing the production of acid by these cells. H 2 antagonists are used in the treatment of dyspepsia, although they have been surpassed in popularity by the more effective [1] proton pump inhibitors.
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.
Famotidine, sold under the brand name Pepcid among others, is a histamine H 2 receptor antagonist medication that decreases stomach acid production. [4] It is used to treat peptic ulcer disease , gastroesophageal reflux disease , and Zollinger-Ellison syndrome . [ 4 ]
Zydis technology was developed by R.P. Scherer Corporation (currently owned by Catalent Pharma Solutions) in 1986. [2] The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine from Merck & Co. was launched in Sweden.
A potassium-competitive acid blocker (PCAB) revaprazan was marketed in Korea as an alternative to a PPI. A newer PCAB vonoprazan with a faster and longer lasting action than revaprazan, and PPIs has been marketed in Japan (2013), Russia (2021), and the US (2023).
Ranitidine has 10% of the affinity that cimetidine has to CYP450, so it causes fewer side effects, but other H 2 blockers famotidine and nizatidine have no CYP450 significant interactions. [131] Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. [132]
You can also try taking over-the-counter acid-reducing medications like famotidine with meals to see if that helps, he says. But it’s unlikely that you’ll deal with this issue for too long.
Nizatidine was developed by Eli Lilly, and was first marketed in 1988. [3] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine.
Ads
related to: alternative for famotidine